Metagenomi Therapeutics, Inc. Gain (Loss) on Disposition of Assets
Metagenomi Therapeutics, Inc. (MGX) reported Gain (Loss) on Disposition of Assets of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2025 was -$502.00K.
- Metagenomi Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2024 was -$1.04M.
| Period end | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 | |
| 2025-12-31 | -$502.00K 10-K · filed 2026-03-05 | |
| 2025-06-30 | -$181.00K 10-Q · filed 2026-08-10 | |
| 2024-12-31 | -$1.04M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |